Bladder Cancer
Kidney Cancer
EAU Edu Platform on Prostate Cancer
Home
Articles
Article of the Month
Editorial
Videos
Webcasts
Education
Curriculum: mPCa patients treatment
Curriculum: CVD risk in PCa patients
E-courses
ESOU Online
Webinars
Guidelines
Events
Home
Articles
Terug
Article of the Month
Editorial
Videos
Webcasts
Education
Terug
Curriculum: mPCa patients treatment
Curriculum: CVD risk in PCa patients
E-courses
ESOU Online
Webinars
Guidelines
Events
Upcoming event
Masterclass on Focal therapy for localised prostate cancer
Home
/
Castration-resistant
Back
Tag:
Castration-resistant
The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells
View
Long-term Safety and Antitumor Activity in the Phase 1–2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer
View
The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer
View
Relationships Between Times to Testosterone and Prostate-Specific Antigen Rises During the First Off-Treatment Interval of Intermittent Androgen Deprivation are Prognostic for Castration Resistance in Men With Nonmetastatic Prostate Cancer
View
PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer
View
Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer
View
Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer Patients
View
